The efficacy of neoadjuvant radiotherapy in patients with signet ring cell carcinoma of the rectum: a retrospective case control study

Introduction: Signet ring cell carcinoma of the rectum (SRCCR) is a rare rectal tumor, therefore, only limited information is available on the management of patients with this diagnosis. Since literature data on the susceptibility of signet ring cell carcinoma to radiation therapy (RT) are controversial, one of the questions that specialists may have is whether the RT is effective as the first stage of treatment.
Materials and methods: We conducted a retrospective analysis of medical records of patients with SRCCR treated at Research Institute FSBI «N. N. Blokhin Oncology Center» of the Ministry of Health of Russia from 1998 to 2020. The inclusion criteria were as follows: histologically confirmed primary SRCCR, disease stage I–III, use of RT or chemoradiotherapy at the first stage. A case control study design was used to select a control group of patients with rectal adenocarcinoma, and each case of the control group was compared with the study group by the following criteria: the year of treatment, the cT and cN clinical stage, the use of RT or CRT. The main endpoint was the rate of Dworak tumor regression grade 3–4; secondary endpoints included 5-year overall survival (OS) and progression-free survival (PFS) rates.
Results: The study and control groups included 16 patients each. In each group, 14 (87,5 %) patients received CRT and 2 (12,5 %) received RT; cT3, cT4 stages were diagnosed in 7 (43,8 %) and 9 (56,3 %) patients, respectively; cN0 and cN1–2 stages were diagnosed in 3 (18,8 %) and 13 (81,2 %) patients, respectively. Eight (50 %) patients in the SRCCR group and 4 (25,0 %) patients in the control group had Dworak tumor regression grade 3–4 (p = 0.273), and one (6,3 %) patient in each group showed pathological complete response (p > 0.99). The 5-year OS in the SRCCR group and the control group was 34,9 % and 51,4 %, respectively (p = 0.833); the 5-year PFS was 30,8 % and 35,6 %, respectively (p = 0.094).
Conclusions: SRCCR is at least as susceptible to RT / CRT as rectal adenocarcinoma, for which neoadjuvant RT / CRT is the standard of care; the use of combination therapy produces comparable long-term results.

1. Hugen, N., et al., Colorectal signet-ring cell carcinoma : benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer, 2015. 136 (2) : p. 333–9.

2. Ling, C. R., et al., Prognosis and value of preoperative radiotherapy in locally advanced rectal signet-ring cell carcinoma. Sci Rep, 2017. 7 : p. 45334.

3. Zhao, Z., et al., The value of adjuvant chemotherapy in stage II / III colorectal signet ring cell carcinoma. Sci Rep, 2020. 10 (1) : p. 14126.

4. Glynne-Jones, R., et al., Rectal cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018. 29 (Suppl 4) : p. iv263.

5. Valentini, V., et al., Evidence and research perspectives for surgeons in the European Rectal Cancer Consensus Conference (EURECA-CC2). Acta Chir Iugosl, 2010. 57 (3) : p. 9–16.

6. Lee, W. S., et al., Treatment outcomes in patients with signet ring cell carcinoma of the colorectum. Am J Surg, 2007. 194 (3) : p. 294–8.

7. Dworak O, K. L., Hoffmann A., Pathological features of rectal cancer after preoperative radiochemotherapy.. International Journal of Colorectal Disease, 1997. 12 (March 1997) : p. 19–23.

8. Pierre A Clavien, J. B., Michelle L de Oliveira, Jean Nicolas Vauthey, Daniel Dindo, Richard D Schulick, Eduardo de Santibañes, Juan Pekolj, Ksenija Slankamenac, Claudio Bassi, Rolf Graf, René Vonlanthen, Robert Padbury, John L Cameron, Masatoshi Makuuchi, The Clavien – Dindo classification of surgical complications : five-year experience. Annals of Surgery, 2009. 250 : p. 187–196.

9. Mizushima, T., et al., Primary colorectal signet-ring cell carcinoma : clinicopathological features and postoperative survival. Surg Today, 2010. 40 (3) : p. 234–8.

10. Wu, S. G., et al., Preoperative radiotherapy improves survival in rectal signet-ring cell carcinoma-a population-based study. Radiat Oncol, 2017. 12 (1) : p. 141.

11. Borger, M. E., et al., Signet ring cell differentiation in mucinous colorectal carcinoma. J Pathol, 2007. 212 (3) : p. 278–86.

12. Rodel, C., et al., Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol, 2005. 23 (34) : p. 8688–96.

13. Kazi, M., et al., Optimal neoadjuvant strategy for signet ring cell carcinoma of the rectum-Is TNT the solution? J Surg Oncol, 2021. 124 (8) : p. 1417–1430.

14. Hugen, N., et al., Modern Treatment of Rectal Cancer Closes the Gap Between Common Adenocarcinoma and Mucinous Carcinoma. Annals of Surgical Oncology, 2015. 22 (8) : p. 2669–2676.

15. Negri, F. V., et al., Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer, 2008. 98 (1) : p. 143–7.